AstraZeneca has announced its plans to construct a new research and development site in Cambridge, Massachusetts. The new facility will also double as the new corporate headquarters of Alexion, which AstraZeneca purchased last July. The company plans to finish the site by 2026 and hopes that its closeness to Boston’s other major institutions and pharma corporations will spur innovation.
According to Fleur Jeffries of PM Live, “The new site will contain over 570,000 square feet of R&D and commercial space that will enable around 1,500 R&D, corporate and commercial staff to come together in a one purpose-built space, with room for future expansion.”
To learn more, click here.
(Source: PM Live, April 29th, 2022)